Pfizer/Astellas Xtandi combined with ADT to treat nmCRPC significantly prolongs OS!

Newborn Astaire and Pfizer recently published the final total life span (OS) analysis results of phase III proser test This study was carried out in patients with non metastatic castration resistant prostate cancer (nmcrpc) to evaluate the efficacy and safety of xtandi (enzalutamide) combined with androgen deprivation therapy (ADT) The results showed that compared with placebo + ADT, the OS of xtandi + ADT group had a statistically significant improvement, reaching the key secondary end point of the study In the preliminary analysis, the adverse events were consistent with those previously reported The detailed efficacy and safety results of the final OS analysis will be published later In 2018, the prosper trial reached the primary end point of metastasis free survival (MFS) The results were published at the 2018 urogenital cancer symposium and later in the New England Journal of medicine Based on the MFS data of this study, xtandi was approved by FDA in July 2018, and combined with ADT to treat adult patients with nmcrpc Globally, prostate cancer is the second leading cause of death in men, second only to lung cancer Xtandi is the best-selling drug in this field It has been approved to treat metastatic castration resistant prostate cancer (mcrpc, August 2012), non metastatic castration resistant prostate cancer (nmcrpc, July 2018), and metastatic castration sensitive prostate cancer (mscspc, December 2019) It is worth mentioning that xtandi is the first and only product approved to treat three unique types of advanced prostate cancer However, xtandi also faces competition pressure from several new products, especially erlada of Johnson & Johnson and nubeqa of Bayer, both of which are new androgen receptor inhibitors At present, erlada has been approved to treat nmcrpc (February 2018) and mcspc (September 2019); nubeqa has been approved nmcrpc (July 2019) In September 2019, Johnson & Johnson released the OS analysis results of erlada's treatment of the critical phase III Spartan of nmcrpc: compared with placebo + ADT, erlead + ADT reduced the risk of death by 25%, but did not reach the statistical significant difference In January 2020, Bayer also published the final OS analysis results of nubeqa in the key phase III Aramis study of nmcrpc: compared with placebo + ADT, the OS of nubeqa + ADT group was significantly prolonged However, specific OS data has not yet been released In cancer clinical trials, OS data is considered the gold standard Some analysts pointed out that the data released by anstar and Pfizer on proser research OS will help consolidate xtandi's market position in CRPC and resist the challenges from J & J erlada and Bayer nubeqa Reference source: Pfizer, astralas' xtandi scores Bayer matching win in extending prostate cancer patients' lives 37